Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) have received a consensus recommendation of “Hold” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $91.50.

A number of equities analysts have issued reports on EGRX shares. BidaskClub downgraded Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Mizuho lowered their price target on Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating on the stock in a research report on Thursday, May 25th. Piper Jaffray Companies set a $118.00 price target on Eagle Pharmaceuticals and gave the stock an “overweight” rating in a research report on Tuesday, May 9th. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 16th. Finally, Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th.

WARNING: “Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Receives Average Recommendation of “Hold” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/25/eagle-pharmaceuticals-inc-nasdaqegrx-receives-average-recommendation-of-hold-from-analysts.html.

Eagle Pharmaceuticals (EGRX) traded up 1.614% on Tuesday, hitting $73.975. The stock had a trading volume of 38,029 shares. The company’s 50 day moving average is $76.50 and its 200-day moving average is $77.91. The stock has a market cap of $1.13 billion, a P/E ratio of 11.626 and a beta of 1.48. Eagle Pharmaceuticals has a 12 month low of $42.33 and a 12 month high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 EPS for the quarter, missing analysts’ consensus estimates of $1.44 by $0.02. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The company had revenue of $76.80 million during the quarter, compared to analysts’ expectations of $70.10 million. During the same quarter in the previous year, the company earned ($0.06) EPS. The firm’s quarterly revenue was up 159.5% compared to the same quarter last year. Analysts forecast that Eagle Pharmaceuticals will post $3.66 EPS for the current year.

In other news, CFO Pete A. Meyers bought 350 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were acquired at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now directly owns 350 shares in the company, valued at approximately $25,021.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders bought 805 shares of company stock worth $61,790. Company insiders own 19.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its position in Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock valued at $128,000 after buying an additional 202 shares during the period. State of Alaska Department of Revenue increased its position in Eagle Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock valued at $125,000 after buying an additional 702 shares during the period. Mason Street Advisors LLC increased its position in Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 175 shares during the period. Bank of Montreal Can increased its position in Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 1,908 shares during the period. Finally, Campbell Newman Asset Management Inc. purchased a new position in Eagle Pharmaceuticals during the first quarter valued at $213,000.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.